Metabolic / GLP-1
GLP-1: Tirzepatide & blends
Also known as Zepbound, Mounjaro, compounded tirzepatide
Dual GIP/GLP-1 receptor agonist studied in type 2 diabetes and chronic weight management.
Where the evidence comes from
97 verified records from 40 countries. The number of studies or countries is not proof that GLP-1: Tirzepatide & blends works or is safe.
Observational human study: 16 · Human clinical trial: 19 · Randomized clinical trial: 35 · Systematic review / meta-analysis: 14 · Narrative review: 12 · Animal study: 1
What is known
Editorial summary not yet written.
What remains uncertain
Editorial summary not yet written.
Conflicting findings
Editorial summary not yet written.
U.S. regulatory status (FDA)
Compound
Product or formulation
FDA status
FDA-approved branded drug
Approved indication
Metara availability (compounded formulation)
Research material (research use only)
Source
Last verified
Notes
Approval applies only to the exact finished drug, formulation and indication. A shared active ingredient does not make a compounded version, blend or other use FDA-approved. Pharmacy or research-material availability is not FDA approval.
International regulatory status
Kept separate from U.S. status. The regulator's country is not the same as where studies took place.
No sourced international decisions recorded yet.
Continue your research
These are two different pathways, not two ways to get the same thing. Neither changes the FDA status shown above.
Clinical care
Available through Metara Health
Explore clinician-guided care and available pharmacy options.
EXPLORE METARA HEALTH →Research materials
Available through BioNex Peptides
Explore research-use materials, lot-specific analytical testing and research documentation.
EXPLORE BIONEX →Limitations
Trial findings do not transfer to compounded or blended products.
Human clinical evidence (70)
Efficacy of Preoperative Tirzepatide, Ketogenic Diet, and Standard Care on 1-Year Weight Loss After One Anastomosis Gastric Bypass (OAGB)
Mario Musella MD · ClinicalTrials.gov · NCT07622992
This registered human study will compare tirzepatide, a ketogenic diet, and standard care before gastric bypass surgery in people with severe obesity. Researchers will assess weight loss after surgery, safety, and obesity-related health conditions. Recruitment has not yet begun, and no results are reported.
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA
Falcon B, Xie CC, Redline S, Grunstein R, Turnbull CD, Rapoport DM, Wang H, Chakladar S, Dimitriadis GK, Lau E, Bednarik J, Liao B, Malhotra A · Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · DOI 10.1007/s44470-026-00162-z
This exploratory analysis of human trial data examined tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. Tirzepatide was associated with improvements in breathing interruptions, sleep-related oxygen deprivation, body weight, and systolic blood pressure across baseline subgroups, generally exceeding placebo. These after-the-fact analyses were intended to generate hypotheses.
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Indiana University · ClinicalTrials.gov · NCT07640139
This human observational study uses existing insurance records to compare adults with employer-provided insurance who have obesity-medication prescriptions with those who do not. It is enrolling by invitation and will examine associations with weight, health, healthcare use, and economic outcomes; no results are reported.
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
Horn DB, Linetzky B, Davies MJ, Laffin LJ, Wang H, Murphy MA, Zimner-Rapuch S, Lau E, Arad AD, Lee CJ · JAMA internal medicine · DOI 10.1001/jamainternmed.2025.6112
This follow-up analysis examined adults with obesity who lost weight on tirzepatide and then switched to placebo in a randomized trial. Greater weight regain after withdrawal was associated with larger increases in waist size, blood pressure, certain cholesterol measures, and average blood sugar.
Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
Tri-Service General Hospital (TSGH) · ClinicalTrials.gov · NCT07589322
This recruiting randomized human trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome. Researchers are measuring body composition, liver fat, strength, heart-related measures, and biological markers; no results are reported.
A Pre-Operative Window Study of Tirzepatide in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center · ClinicalTrials.gov · NCT07065552
This registered human trial is examining whether tirzepatide affects cancer cell growth before surgery in patients with obesity-driven endometrial cancer. Researchers will compare tumor tissue collected before and after treatment. The trial is recruiting, and no results are reported; potential effects on tumor growth remain a hypothesis.
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis
Sattar N, Linetzky B, Ruotolo G, Verma S, Sourij H, Wang H, Vanderman K, Wilson JM, Griffin RM, Stefanski A, Ridker PM · Journal of the American College of Cardiology · DOI 10.1016/j.jacc.2026.04.044
This follow-up analysis of a human trial compared cardiovascular risk markers in blood samples from adults with overweight or obesity receiving tirzepatide or placebo. Tirzepatide was associated with improvements in markers of metabolism, body fat, liver stress, and blood vessel function, plus selected inflammation and clotting markers. The analysis examined biomarkers rather than cardiovascular events.
Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial
National Taiwan University Hospital · ClinicalTrials.gov · NCT07382024
This registered randomized human trial will test whether tirzepatide reduces persistent atrial fibrillation, an irregular heart rhythm, after catheter ablation in adults with overweight or obesity. It will also assess weight, metabolic health, and safety compared with standard care alone. The trial is not yet recruiting, and no results are available.
Systematic & narrative reviews (26)
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies
Paccola GP, de Oliveira RF, Mochetti MM, Razera FPM, Vecchi R, Montanher RCP · Clinical obesity · DOI 10.1111/cob.70111
This systematic review combined trials and observational studies comparing tirzepatide with semaglutide in adults with overweight or obesity. Tirzepatide was associated with greater weight loss and improved long-term blood sugar levels, but serious adverse events were more frequent. Overall side effects, digestive side effects, and treatment discontinuation due to adverse events did not differ significantly.
Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis
Silva JPMRJ, Nogueira BV, Sartori DL, da Silva JRC, Sciota LBA, de Mendonça Bisneto OI, Gomes WF · Diabetes, obesity & metabolism · DOI 10.1111/dom.71051
This review compared cardiovascular outcomes with tirzepatide versus GLP-1 receptor agonists in adults with overweight or obesity. Tirzepatide was not associated with a statistically significant reduction in major cardiovascular events. Substantial differences between studies and the predominance of observational evidence limit conclusions about cause and effect.
Tirzepatide data: safety first is safety always!
Janić M, Rabbani SA, El-Tanani M, Rangraze I, Janež A, Maggio V, Rizzo M · Expert opinion on drug safety · DOI 10.1080/14740338.2026.2681511
This review examined human clinical trials and real-world evidence on tirzepatide for type 2 diabetes and obesity. It described blood sugar and weight benefits alongside digestive side effects, a high comparative risk of severe digestive events and treatment discontinuation, and rare gallbladder and thyroid risks. The authors highlighted the need to study long-term physical function and potential muscle loss.
Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review
Mady R, Tafazal H, Soliman H, Ramadan A, Hajaj M · Cureus · DOI 10.7759/cureus.111445
This review examined tirzepatide, breast cancer risk, and breast imaging using human and preclinical evidence. Human trial data showed no clear evidence of increased breast cancer incidence, while the clinical relevance of reduced tumor progression in preclinical models remains uncertain. Weight loss may change breast appearance and make existing benign lumps easier to feel, without evidence of reduced imaging accuracy.
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Parlati AL, Martini L, Nardi E, Carluccio R, Parlati LE, Madaudo C, Perrone Filardi P · Clinical Medicine Insights. Cardiology · DOI 10.1177/11795468261460202
This review examined tirzepatide evidence in people with diabetes, obesity, and related heart or kidney conditions. It reported improved blood sugar, weight, and cardiovascular risk factors, with exploratory evidence of kidney benefits. Major cardiovascular event outcomes were no worse than with dulaglutide, while a trial in obesity-related heart failure found fewer worsening heart failure events and improved health status.
Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review
La Vignera S, Condorelli RA · Medicina (Kaunas, Lithuania) · DOI 10.3390/medicina62081536
This systematic review examined whether the day of semaglutide or tirzepatide administration affects outcomes in adults with type 2 diabetes or obesity. No studies directly compared different weekdays for the injectable drugs, so current evidence does not support an optimal day. Suggestions that flexible schedules may help adherence and tolerability came mainly from indirect evidence and expert opinion.
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis
Spiazzi BF, Zingano CP, Colpani V, Gerchman F · Diabetes research and clinical practice · DOI 10.1016/j.diabres.2026.113431
This systematic review pooled randomized trials of tirzepatide in adults with type 2 diabetes or overweight or obesity. Tirzepatide was associated with fewer major cardiovascular events considered together and fewer deaths from any cause. No association was found for individual cardiovascular event types or heart failure hospitalizations.
Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives
Cadena-Ullauri S, Cadena Paredes AS, Guamán-Herrera L, Imbaquingo-Espinales J, Ruiz-Pozo VA, Tamayo-Trujillo R, Guevara-Ramírez P, Paz-Cruz E, Zambrano AK · Frontiers in microbiology · DOI 10.3389/fmicb.2026.1901528
This review examined research on obesity, gut microbes, and tirzepatide rather than reporting a new experiment. Evidence suggests tirzepatide may be associated with changes in gut microbes, their products, intestinal barrier function, and inflammation. Whether these changes are direct drug effects or consequences of weight loss, dietary changes, or improved blood sugar control remains unclear.
Laboratory, animal & other research (1)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ · JCI insight · DOI 10.1111/dom.13358
This animal and laboratory study examined how tirzepatide activates GIP and GLP-1 receptors, including experiments in insulin-producing pancreatic cells. Tirzepatide engaged GIP receptors more strongly and favored particular signals at GLP-1 receptors. These differences may enhance insulin release and help explain its promising effects on metabolism.
Browse worldwide evidence → · Search and filter all GLP-1: Tirzepatide & blends studies →
Next steps
Profile last reviewed September 26, 2026. Educational content only. Not medical advice, a dosing protocol or a treatment recommendation.